Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 4/17/2018 |
| Start Date: | September 1, 2015 |
| End Date: | February 2019 |
| Contact: | Madhukar Thakur, PhD |
| Phone: | 215-503-7874 |
A Pilot Phase I Open Label Study of Cu-64-TP3805 PET Imaging for Detection of Prostate Cancer in Men With Persistently Elevated PSA
This pilot phase I trial studies how well copper Cu 64 TP3805 positron emission tomography
(PET) works in detecting prostate cancer in patients with persistently elevated prostate
specific antigen (PSA). The copper Cu 64 TP3805 PET scan uses copper Cu 64 TP3805, a compound
made of a radioactive agent attached to a molecule that looks like a hormone that binds to
cancer cells to detect prostate cancer during PET scans. Copper Cu 64 TP3805 PET may be able
to see tumors at an earlier stage than the standard of care.
(PET) works in detecting prostate cancer in patients with persistently elevated prostate
specific antigen (PSA). The copper Cu 64 TP3805 PET scan uses copper Cu 64 TP3805, a compound
made of a radioactive agent attached to a molecule that looks like a hormone that binds to
cancer cells to detect prostate cancer during PET scans. Copper Cu 64 TP3805 PET may be able
to see tumors at an earlier stage than the standard of care.
PRIMARY OBJECTIVES:
I. To assess the ability of Cu-64-TP3805 (copper Cu 64 TP3805) to detect prostate cancer
(PC), or absence thereof, within the prostate gland.
I. To assess the ability of Cu-64-TP3805 (copper Cu 64 TP3805) to detect prostate cancer
(PC), or absence thereof, within the prostate gland.
Inclusion Criteria:
- Ability to provide signed informed consent and willingness to comply with protocol
requirements
- Persistently elevated PSA
- Scheduled for magnetic resonance imaging (MRI) fusion/transrectal ultrasound (TRUS)
biopsy, followed by histology
- Agree to use an acceptable form of birth control for a period of 7 days after the
Cu-64-TP3805 injection
Exclusion Criteria:
- Participating would significantly delay the scheduled standard of care therapy
- Administered a radioisotope within 10 physical half-lives prior to study drug
injection
- Have any medical condition or other circumstances that, in the opinion of the
investigator, would significantly decrease obtaining reliable data, achieving study
objectives or completing the study
We found this trial at
1
site
1020 Walnut St
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19107
(215) 955-6000
Phone: 215-503-7874
Thomas Jefferson University We are dedicated to the health sciences and committed to educating professionals,...
Click here to add this to my saved trials
